MIAMI, FL — August 8, 2025 — BiotechReporter.news — Longeveron Inc. (NASDAQ: LGVN) announced the pricing of a public offering of 5,882,354 shares of Class A common stock, or pre-funded warrants, along with short-term warrants for up to 14,705,885 Class A shares at $0.85 per share.
The short-term warrants, priced at $0.85 per share, are immediately exercisable for 24 months. Certain board members and insiders are participating under the same terms. The offering is set to close around August 11, 2025, pending standard conditions.
H.C. Wainwright & Co. is the exclusive placement agent. The offering is projected to yield $5.0 million before fees, with potential additional proceeds of $12.5 million if short-term warrants are fully exercised. The company plans to use the funds for laromestrocel’s clinical and regulatory advancement, including HLHS, Alzheimer’s, and pediatric DCM treatments, regulatory approvals, CMC activities, capital expenditures, and general corporate needs.
These securities are offered under a registration statement on Form S-1, filed with the SEC on August 4, 2025, and effective on August 8, 2025. The offering is made via a prospectus. Electronic copies are available on the SEC’s website or from H.C. Wainwright & Co., LLC.
This announcement is not an offer to sell or a solicitation to buy securities in any jurisdiction where such action would be unlawful.
Derek Cole, Investor Relations Advisory Solutions, derek.cole@iradvisory.com
Source: Longeveron Inc.
